Semax is a stabilized synthetic analog of the adrenocorticotropic hormone fragment ACTH(4–10), designed to resist enzymatic degradation and enhance central nervous system bioavailability[5][11]. Preclinical and clinical research indicates that Semax modulates BDNF expression, supports neuronal survival, and influences monoaminergic neurotransmission[1]. In human studies, Semax has demonstrated cognitive‑enhancing effects in patients with cerebrovascular conditions and minimal brain dysfunction, with courses typically lasting 10–30 days at daily intranasal doses of 200–6,000 mcg depending on severity[2][3]. When administered subcutaneously, systemic absorption is more sustained compared to the intranasal route, potentially allowing once‑daily dosing[4].
